HUTCHMED (CHINA) LS-1
Research HUTCHMED (CHINA) LS-1 (H7T2) on Bullrun: market cap EUR 1.47B, P/E 3.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerH7T2
- ExchangeF
- CountryHong Kong
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 1.47B
- P/E3.6
- Financial periodFY2025
- RevenueEUR 548.51M
- Revenue growth-13.0%
- Net incomeEUR 456.91M
- Free cash flow-EUR 88.81M
- Gross margin38.7%
Valuation Snapshot
latest market cap is EUR 1.47B; P/E is 3.6.
About HUTCHMED (CHINA) LS-1
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
Frequently asked questions
What is HUTCHMED (CHINA) LS-1's market cap?
HUTCHMED (CHINA) LS-1's market capitalization is EUR 1.47B.
What is HUTCHMED (CHINA) LS-1's P/E ratio?
HUTCHMED (CHINA) LS-1's price-to-earnings (P/E) ratio is 3.6.
What does HUTCHMED (CHINA) LS-1 do?
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.